Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Apr;91(4):424–432. doi: 10.1111/j.1349-7006.2000.tb00962.x

Schedule‐dependent Interactions between Raltitrexed and Cisplatin in Human Carcinoma Cell Lines in vitro

Yasuhiko Kano 1,✉, Miyuki Akutsu 1, Kenichi Suzuki 2, Yasuo Yazawa 3, Saburo Tsunoda 1
PMCID: PMC5926465  PMID: 10804291

Abstract

Raltitrexed (‘Tomudex”) is a new anticancer agent which inhibits thymidylate synthase. To provide a rational basis for clinical trial design of the combination of raltitrexed and cisplatin, we studied the cytotoxic effects of this combination using various schedules in vitro and four human colon cancer cell lines, Colo201, Colo320, LoVo, and WiDr. Cell growth inhibition after 5 days was determined by using 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) reduction assay. The effects of drug combinations at the concentration producing 80% cell growth inhibition (IC80) level were analyzed by the isobologram method. Simultaneous exposure to raltitrexed and cisplatin for 24 h, and sequential exposure to raltitrexed followed by cisplatin produced additive effects in the Colo201, Colo320, and LoVo cells, and additive and synergistic effects in WiDr cells. Sequential exposure to cisplatin followed by raltitrexed produced additive effects in the Colo201 cells and antagonistic effects in other three cell lines. Simultaneous and continuous exposure to both agents for 5 days produced additive effects in all four cell lines. These findings suggest that the simultaneous administration of raltitrexed and cisplatin, or the sequential administration of raltitrexed followed by cisplatin, generally produce the expected cytotoxicity at the cellular level and are optimal schedules, while the sequential administration of cisplatin followed by raltitrexed produces antagonistic effects and is inappropriate for this combination. Further in vivo and clinical studies will be necessary to determine the toxicity and antitumor effects of this schedule.

Keywords: Raltitrexed, Cisplatin, Drug combination, Isobologram

Full Text

The Full Text of this article is available as a PDF (124.6 KB).

REFERENCES

  • 1. ) Jackman , A. L. , Taylor , G. A. , O'Connor , B. M. , Bishop , J. A. , Moran , R. G. and Calvert , A. H.Activity of the thymidylate synthase inhibitor 2‐desamino‐N10‐propargyl‐5,8‐dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo . Cancer Res. , 50 , 50 – 5212 ( 5218. ). [PubMed] [Google Scholar]
  • 2. ) Jackman , A. L. , Taylor , G. A. , Gibson , W. , Kimbell , R. , Brown , M. , Calvert , A. H. , Judson , I. R. and Hughes , L. R.ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study . Cancer Res. , 51 , 5579 – 5586 ( 1991. ). [PubMed] [Google Scholar]
  • 3. ) Clarke , S. J. , Hanwell , J. , de Boer , M. , Planting , A. , Verweij , J. , Walker , M. , Smith , R. , Jackman , A. L. , Hughes , L. R. , Harrap , K. R. , Kennealey , G. T. and Judson , I. R.Phase I trial of ZD1694, a new folate‐based thymidylate synthase inhibitor, in patients with solid tumors . J. Clin. Oncol. , 14 , 1495 – 1503 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Beale , P. , Judson , I. , Hanwell , J. , Berry , C. , Aherne , W. , Hickish , T. , Martin , P. and Walker , M.Metabolism, excretion and pharmacokinetics of a single dose of [14C]raltitrexed in cancer patients . Cancer Chemother. Pharmacol. , 42 , 71 – 76 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Blackledge , G.New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed (‘Tomudex’) . Br. J. Cancer , 77 ( Suppl. 2 ), 29 – 37 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. ) Smith , I. , Jones , A. , Spielmann , M. , Namer , M. , Green , M. D. , Bonneterre , J. , Wander , H. E. , Hatschek , T. , Wilking , N. , Zalcberg , J. , Spiers , J. and Seymour , L.A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor . Br. J. Cancer , 74 , 479 – 481 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Cunningham , D.Mature results from three large controlled studies with raltitrexed ('Tomudex') . Br. J. Cancer , 77 ( Suppl. 2 ), 15 – 21 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Meropol , N. J. , Pazdur , R. , Vincent , M. , Willson , J. K. , Kelsen , D. P. and Douglass , H. O. , Jr.Phase II study of ZD1694 in patients with advanced gastric cancer . Am. J. Clin. Oncol. , 19 , 628 – 630 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Pazdur , R. , Meropol , N. J. , Casper , E. S. , Fuchs , C. , Douglass , H. O. , Jr. , Vincent , M. and Abbruzzese , J. L.Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer . Invest. New Drugs , 13 , 355 – 358 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Smith , I. , Jones , A. , Spielmann , M. , Namer , M. , Green , M. D. , Bonneterre , J. , Wander , H. E. , Hatschek , T. , Wilking , N. , Zalcberg , J. , Spiers , J. and Seymour , L.A phase II study in advanced breast cancer: ZD1694 (‘Tomudex’) a novel direct and specific thymidylate synthase inhibitor . Br. J. Cancer , 74 , 479 – 481 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. ) Rougier , P. , Ducreux , M. , Kerr , D. , Carr , B. I. , Francois , E. , Adenis , A. and Seymour , L.A phase II study of raltitrexed (‘Tomudex’) in patients with hepatocellular carcinoma . Ann. Oncol. , 8 , 500 – 502 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Harper , P.Advanced colorectal cancer (ACC): results from the latest Tomudex (raltitrexed) comparative study . Proc. Am. Soc. Clin. Oncol. , 16 , 228a ( 1997. ). [Google Scholar]
  • 13. ) Pazdur , R. and Vincent , M.Raltitrexed (‘Tomudex’) versus 5‐fluorouracil and leucovorin (5‐FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter North American trial . Proc. Am. Soc. Clin. Oncol. , 16 , 228a ( 1997. ). [Google Scholar]
  • 14. ) Pinto , A. and Lippard , S. J.Binding of the antitumor drug (II) (cisplatin) to DNA . Biochim. Biophys. Acta , 780 , 167 – 180 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Masuda , H. , Ozols , R. F. , Lai , G. M. , Foji , A. , Rothenberg , M. and Hamilton , T. C.Increased DNA repair as a mechanism of acquired resistance to cis‐diamminedichloroplatinum(II) in ovarian cancer cell lines . Cancer Res. , 48 , 5713 – 5716 ( 1988. ). [PubMed] [Google Scholar]
  • 16. ) Bedford , P. , Fichtinger‐Schepman , A. M. J. , Shellard , S. A. , Walker , M. C. , Masters , J. R. W. and Hill , B. T.Differential repair of platinum‐DNA adducts in human bladder and testicular tumor continuous cell lines . Cancer Res. , 48 , 3019 – 3024 ( 1998. ). [PubMed] [Google Scholar]
  • 17. ) Kelland , L. R. , Kimbell , R. , Hardcastle , A. , Aherne , G. W. and Jackman , A. L.Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumor cell lines . Eur. J. Cancer , 31A , 981 – 986 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Fizazi , K. , Soria , J. C. , Bonny , M. , Ruffie , P. , Ducreux , M. , Le Chevalier , T. , Couturas , O. , Poterre , M. and Armand , J. P.Phase I/II dose‐finding and pharmacokinetic study of Tomudex in combination with oxaliplatin in advanced solid tumor . Proc. Am. Soc. Clin. Oncol. , 17 , 20a ( 1998. ). [Google Scholar]
  • 19. ) Ackland , S. , Kuiper , C. M. , Carg , M. , Bergman , A. M. , Smid , K. and Peters , G. J.Variable effects of the combination of Tomudex (ZD1694) and cisplatin in ovarian cancer cell lines . Ann. Oncol. , 7 , 7 ( 1996. ). [Google Scholar]
  • 20. ) Raymond , E. , Djelloul , S. , Buquest‐Fagot , C. , Goldwasser , F. , Mester , J. , Cvitkovic , E. , Louvet , C. and Gespach , C.Oxaliplatin and cisplatin in combination with 5FU, specific thymidylate synthase inhibitors (AG337, ZD1694) and topoisomerase I inhibitors (SN‐38, CPT‐11) in human colonic, ovarian and breast cancers . Proc. Am. Assoc. Cancer Res. , 37 , 291a ( 1996. ). [Google Scholar]
  • 21. ) Jackman , A. L. , Kimbell , R. and Ford , H. E. R.Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations . Eur. J. Cancer , 35 ( Suppl. 1 ), S3 – S8 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Steel , G. G. and Peckham , M. J.Exploitable mechanisms in combined radiotherapy‐chemotherapy: the concept of additivity . Int. J. Radiat. Oncol. Biol. Phys. , 5 , 85 – 91 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Kano , Y. , Sakamoto , S. , Kasahara , T. , Akutsu , M. , Inoue , Y. and Miura , Y.In vitro effects of amsacrine in combination with other anticancer agents . Leuk. Res. , 15 , 1059 – 1064 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Rideout , D. C. and Chou , T. C.Synergism, antagonism, and potentiation of chemotherapy . In“Synergism and Antagonism in Chemotherapy ,” ed. Chou T. C. and Rideout D. C. , pp. 3 – 60 ( 1991. ). Academic Press; , San Diego . [Google Scholar]
  • 25. ) Berenbaum , M. C.What is synergy ? Pharmacol. Rev. , 41 , 93 – 141 ( 1988. ). [PubMed] [Google Scholar]
  • 26. ) Greco , W. R. , Bravo , G. and Parsons , J. C.The search for synergy: a critical review from a response surface perspective . Pharmacol. Rev. , 47 , 331 – 385 ( 1995. ). [PubMed] [Google Scholar]
  • 27. ) Frey , C. M.Role of modelling in joint action studies . J. Natl. Cancer Inst. , 86 , 1493 – 1495 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Kano , Y. , Ohnuma , T. , Okano , T. and Holland , J. F.Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture . Cancer Res. , 48 , 351 – 356 ( 1988. ). [PubMed] [Google Scholar]
  • 29. ) Kano , Y. , Suzuki , K. , Akutsu , M. , Suda , K. , Inoue , Y. , Yoshida , M. , Sakamoto , S. and Miura , Y.Effects of CPT‐11 in combination with other anticancer agents in culture . Int. J. Cancer , 50 , 604 – 610 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Kano , Y. , Akutsu , M. , Tsunoda , S. , Suzuki , K. and Adachi , K.In vitro schedule‐dependent interaction between raltitrexed and SN‐38 (the active metabolite of irinotecan) in human carcinoma cell lines . Cancer Chemother. Pharmacol. , 42 , 91 – 98 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Sorenson , C. M. and Eastman , A.Mechanism of cis‐diamminedichloroplatinum(II)‐induced cytotoxicity: role of G2 arrest and DNA double‐strand breaks . Cancer Res. , 48 , 4484 – 4488 ( 1988. ). [PubMed] [Google Scholar]
  • 32. ) Jackmann , R. C.Biological effects of folic acid antagonists with antineoplastic activity . Pharmacol. Ther. , 25 , 61 – 82 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Inaba , M. , Mitsuhashi , J. and Ozawa , S.Kinetic analysis of 5‐fluorouracil action against various cancer cells . Jpn. J. Cancer Res. , 81 , 1039 – 1044 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES